SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-000539
Filing Date
2024-01-03
Accepted
2024-01-03 08:30:08
Documents
12
Period of Report
2023-12-28
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K cadl-20231228.htm   iXBRL 8-K 40454
  Complete submission text file 0000950170-24-000539.txt   164190

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cadl-20231228.xsd EX-101.SCH 2464
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cadl-20231228_lab.xml EX-101.LAB 15935
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cadl-20231228_pre.xml EX-101.PRE 11450
6 EXTRACTED XBRL INSTANCE DOCUMENT cadl-20231228_htm.xml XML 4884
Mailing Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494
Business Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494 617-916-5445
Candel Therapeutics, Inc. (Filer) CIK: 0001841387 (see all company filings)

IRS No.: 522214851 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40629 | Film No.: 24504418
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)